预约演示
更新于：2026-10-05
Maridebart Cafraglutide
抗GIPR 抗体（安进）
更新于：2026-10-05
概要
基本信息
药物类型 多肽-抗体偶联药物 |
别名 Anti-GIPR Antibody (Amgen)、MariTide、AMG-133 + [1] |
作用方式 拮抗剂、激动剂 |
作用机制 GIPR 拮抗剂(肠抑胃肽受体 拮抗剂)、GLP-1R激动剂(胰高血糖素样肽-1激动剂) |
在研适应症 |
非在研适应症- |
原研机构 |
非在研机构 |
权益机构- |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
结构/序列
使用我们的ADC技术数据为新药研发加速。
登录
或
Sequence Code 13456153L
来源: *****
Sequence Code 319324125H
来源: *****
Sequence Code 1031376808
来源: *****
关联
28
项与 抗GIPR 抗体（安进） 相关的临床试验NCT07832799
A Phase 1, Open-label, Randomized, Parallel Group Study to Assess the Relative Bioavailability of Two Maridebart Cafraglutide (AMG 133) Drug Products in Participants Living With Overweight or Obesity
NCT07684144
A Phase 3, Randomized, Double-Blind Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Participants With Obesity or Overweight With Type 2 Diabetes Mellitus
NCT07684235
A Phase 3, Randomized, Double-Blind Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Participants With Obesity or Overweight
100 项与 抗GIPR 抗体（安进） 相关的临床结果
登录后查看更多信息
100 项与 抗GIPR 抗体（安进） 相关的转化医学
登录后查看更多信息
100 项与 抗GIPR 抗体（安进） 相关的专利（医药）
登录后查看更多信息
17
项与 抗GIPR 抗体（安进） 相关的文献（医药）2026-09-01DIABETES OBESITY & METABOLISM
A Sequential Dual
GLP
‐
1R
/
GIPR
Agonist‐To‐Antagonist Molecule Achieves Superior Weight Loss in Obese Mice
Article
作者: Peng, Dezheng ; Tang, Dongfang ; Peng, Binhui ; Wang, Zhaofeng ; Wu, Peng ; Zhang, Yunxiao ; Wang, Yongchen ; Feng, Xinyu ; Zhu, Bo ; Liu, Yu ; Zhong, Guyu
ABSTRACT:
Background:
The GLP‐1 receptor (GLP‐1R) and GIP receptor (GIPR) are key targets for diabetes and obesity therapies. Pharmacological agents including GLP‐1R agonists (e.g., Semaglutide), dual GLP‐1R/GIPR agonists (e.g., Tirzepatide) and a GLP‐1R agonist/GIPR antagonist (AMG133) have demonstrated considerable promise in anti‐diabetic and weight management applications. However, a systematic comparison of the specific contributions of GIPR activation versus GIPR inhibition to weight loss within the context of GLP‐1/GIP dual‐targeting therapies remains unexplored.
Research Design and Methods:
To address this, we designed three IgG4 Fc‐fusion proteins: a GLP‐1R agonist/GIPR agonist, (i) GLP‐1(A8G)/GIP(A2G)‐Fc; a GLP‐1R agonist/GIPR inhibitor, (ii) GLP‐1(A8G)/GIP(3–30)‐Fc; and a sequential molecule that hypothesised to transition from dual GLP‐1R/GIPR agonism to GLP‐1R agonism/GIPR inhibition, (iii) GLP‐1(A8G)/GIP(1–30)‐Fc. Mono‐agonist GLP‐1(A8G)‐Fc and dual‐agonist GLP‐1(A8G)/GIP(A2G)‐Fc were used as controls to investigate the weight loss effects of GIPR activation and inhibition in DIO mice.
Results:
Our findings revealed that the sequential molecule GLP‐1(A8G)/GIP(1–30)‐Fc produced the greatest body weight reduction (21.59%), significantly outperforming GLP‐1(A8G)/GIP(3–30)‐Fc (14.5%;
p
< 0.001). Furthermore, both GIPR activation and inhibition, when combined with GLP‐1R agonism, markedly improved serum and hepatic lipid metabolism, as evidenced by reduced triglycerides and total cholesterol.
Conclusion:
Together, these findings validate a peptide‐based inhibitory strategy for synergistic weight loss and provide insights into the differential metabolic roles of GIPR activation versus inhibition, guiding the development of novel anti‐obesity therapeutics.
2026-05-01LIFE SCIENCES
Retraction notice to “Chronic treatment with anti-GIPR mAb alone and combined with DPP-4 inhibitor correct obesity, dyslipidemia and nephropathy in rodent animals” [Life Sciences 269 (2021) 119038]
Article
作者: Wang, Huiyang ; Chen, Jiawei ; Hu, Yongbin ; Mou, Xin ; Zheng, Songsong
2026-03-11ENDOCRINE REVIEWS
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity
Review
作者: Son, Jang Won ; Lim, Soo ; Blüher, Matthias ; Nauck, Michael A ; le Roux, Carel W
Abstract:
The approvals of semaglutide and tirzepatide have set new benchmarks in the treatment of type 2 diabetes and obesity. Building on their success, novel glucagon-like peptide-1 (GLP-1)-based therapeutics are rapidly advancing. These next-generation agents engage not only GLP-1 receptors but also those for other gastro-entero-pancreatic hormones such as glucose-dependent insulinotropic polypeptide (GIP), glucagon, amylin, and peptide YY to enhance energy uptake, storage, and expenditure through synergistic mechanisms. Both GIP receptor agonism and antagonism, particularly in combination with GLP-1 receptor agonism, have shown promise. Maridebart cafraglutide, combining GLP-1 receptor agonism with GIP receptor antagonism, exemplifies this innovative approach. Glucagon coagonists like survodutide and mazdutide have demonstrated significant weight loss and improved glycemic control. Amylin-based agents, including CagriSema (cagrilintide + semaglutide) and amycretin, enhance satiety and glycemic outcomes through complementary actions. Further innovation is seen in triple agonists such as retatrutide, which targets GIP, GLP-1, and glucagon receptors to amplify metabolic effects. Meanwhile, the emergence of orally active small-molecule GLP-1 receptor agonists like danuglipron and orforglipron, which are resistant to enzymatic degradation, marks a major advance in patient-friendly drug delivery. This review explores the mechanisms, clinical development, and therapeutic potential of these novel agents, excluding already approved drugs like liraglutide, semaglutide, and tirzepatide. We highlight how multireceptor agonists and oral GLP-1-based therapies may reshape the future landscape of obesity and type 2 diabetes treatment by offering more effective and better-tolerated options.
445
项与 抗GIPR 抗体（安进） 相关的新闻（医药）2026-09-29
2026-09-23
100 项与 抗GIPR 抗体（安进） 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 阻塞性睡眠呼吸暂停综合征 | 临床3期 | 美国 | 2025-11-25 | |
| 阻塞性睡眠呼吸暂停综合征 | 临床3期 | 日本 | 2025-11-25 | |
| 阻塞性睡眠呼吸暂停综合征 | 临床3期 | 澳大利亚 | 2025-11-25 | |
| 阻塞性睡眠呼吸暂停综合征 | 临床3期 | 巴西 | 2025-11-25 | |
| 阻塞性睡眠呼吸暂停综合征 | 临床3期 | 加拿大 | 2025-11-25 | |
| 阻塞性睡眠呼吸暂停综合征 | 临床3期 | 捷克 | 2025-11-25 | |
| 阻塞性睡眠呼吸暂停综合征 | 临床3期 | 法国 | 2025-11-25 | |
| 阻塞性睡眠呼吸暂停综合征 | 临床3期 | 德国 | 2025-11-25 | |
| 阻塞性睡眠呼吸暂停综合征 | 临床3期 | 匈牙利 | 2025-11-25 | |
| 阻塞性睡眠呼吸暂停综合征 | 临床3期 | 波兰 | 2025-11-25 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 592 | Maridebart Cafraglutide 140mg/280mg/420mg | 衊齋遞選鏇遞窪觸鏇淵(獵齋鏇鹽膚壓淵構膚齋) = 糧襯積積積鬱願鬱獵網 遞網構製齋糧鑰壓憲窪 (艱築觸鬱衊鏇壓鹹顧糧 ) 更多 | 积极 | 2025-06-23 | ||
Placebo | 衊齋遞選鏇遞窪觸鏇淵(獵齋鏇鹽膚壓淵構膚齋) = 築鏇獵獵襯積顧餘憲鹹 遞網構製齋糧鑰壓憲窪 (艱築觸鬱衊鏇壓鹹顧糧, -4.2 ~ -0.7) 更多 | ||||||
临床1期 | - | 34 | (Japanese Participants: AMG 133 Low Dose) | 糧網鑰選簾構製網鹽選(選觸衊鹽範膚鏇膚廠淵) = 構築衊餘夢艱鹽獵膚襯 鹽齋艱製廠蓋齋窪醖製 (壓衊願餘構襯鹽醖廠範, 57.3) 更多 | - | 2025-02-25 | |
(Japanese Participants: AMG 133 Medium Dose) | 糧網鑰選簾構製網鹽選(選觸衊鹽範膚鏇膚廠淵) = 構壓繭鹽鹽壓襯膚憲廠 鹽齋艱製廠蓋齋窪醖製 (壓衊願餘構襯鹽醖廠範, 24.1) 更多 | ||||||
临床2期 | 592 | (Without Type 2 Diabetes) | 艱積構繭網簾餘醖願製(糧鹽觸齋衊襯願鑰糧糧) = Without Type 2 Diabetes: MariTide Demonstrated up to ~20% Average Weight Loss at 52 Weeks Without a Weight Loss Plateau; With Type 2 Diabetes: MariTide Delivered an Impressive up to ~17% Average Weight Loss at 52 Weeks Without a Weight Loss Plateau 觸夢選襯衊鬱顧糧蓋積 (餘網築遞築醖窪築糧蓋 ) 更多 | 积极 | 2024-11-26 | ||
Placebo (Without Type 2 Diabetes) | |||||||
临床1期 | 75 | 鑰醖淵蓋憲窪蓋積築膚(糧壓壓顧膚窪衊蓋鏇顧) = 糧簾築憲餘齋觸鹽餘淵 願選鬱積廠鏇鑰衊選蓋 (觸壓構範壓簾簾壓蓋遞 ) | 积极 | 2022-11-07 | |||
Placebo | 鑰醖淵蓋憲窪蓋積築膚(糧壓壓顧膚窪衊蓋鏇顧) = 願鑰觸齋鏇膚遞構積範 願選鬱積廠鏇鑰衊選蓋 (觸壓構範壓簾簾壓蓋遞 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用